About NEOS Therapeutics
NEOS Therapeutics is a company based in Grand Prairie (United States) founded in 2008.. NEOS Therapeutics has raised $94.64 million across 7 funding rounds from investors including Burrill and Company, Deerfield and Presidio Partners. The company has 150 employees as of June 30, 2023. NEOS Therapeutics offers products and services including ADHD Therapeutics, Pediatrics Products, RxCONNECT, and AR101 (enzastaurin). NEOS Therapeutics operates in a competitive market with competitors including Nura Bio, Healx, Cingulate, STALICLA and PaxMedica, among others.
- Headquarter Grand Prairie, United States
- Employees 150 as on 30 Jun, 2023
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aytu Biopharma, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$94.64 M (USD)
in 7 rounds
-
Latest Funding Round
$60 M (USD), Debt – Conventional
May 16, 2016
-
Investors
Burrill and Company
& 5 more
-
Employee Count
150
as on Jun 30, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NEOS Therapeutics
NEOS Therapeutics offers a comprehensive portfolio of products and services, including ADHD Therapeutics, Pediatrics Products, RxCONNECT, and AR101 (enzastaurin). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatments for Attention Deficit-Hyperactivity Disorder symptoms.
Products addressing pediatric allergies and deficiencies.
Program for managing prescription therapeutics access.
Therapeutic in development for complex health conditions.
Unlock access to complete
Unlock access to complete
Funding Insights of NEOS Therapeutics
NEOS Therapeutics has successfully raised a total of $94.64M across 7 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $60 million completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Debt – Conventional — $60.0M
-
First Round
First Round
(20 Nov 2009)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2016 | Amount | Debt – Conventional - NEOS Therapeutics | Valuation |
investors |
|
| Feb, 2015 | Amount | Series D - NEOS Therapeutics | Valuation | Presidio Partners , Delaware Street Capital | |
| Apr, 2014 | Amount | Series C - NEOS Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NEOS Therapeutics
NEOS Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Burrill and Company, Deerfield and Presidio Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
US, Canada, and China are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NEOS Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NEOS Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neos Therapeutics Comparisons
Competitors of NEOS Therapeutics
NEOS Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nura Bio, Healx, Cingulate, STALICLA and PaxMedica, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Diagnostic solutions and neuroprotective medicines for neurological disorders are provided.
|
|
| domain | founded_year | HQ Location |
AI-powered drug discovery platform for rare diseases is developed.
|
|
| domain | founded_year | HQ Location |
Cingulate is focused on developing treatments for ADHD and anxiety.
|
|
| domain | founded_year | HQ Location |
Precision medicines for neurodevelopmental disorders are manufactured using DEPI technology.
|
|
| domain | founded_year | HQ Location |
Drugs for neurodevelopmental disorders are developed by PaxMedica.
|
|
| domain | founded_year | HQ Location |
Drugs are developed to treat multiple neurological disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Neos Therapeutics
Frequently Asked Questions about NEOS Therapeutics
When was NEOS Therapeutics founded?
NEOS Therapeutics was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Where is NEOS Therapeutics located?
NEOS Therapeutics is headquartered in Grand Prairie, United States. It is registered at Grand Prairie, Texas, United States.
Is NEOS Therapeutics a funded company?
NEOS Therapeutics is a funded company, having raised a total of $94.64M across 7 funding rounds to date. The company's 1st funding round was a Series C of $2.5M, raised on Nov 20, 2009.
How many employees does NEOS Therapeutics have?
As of Jun 30, 2023, the latest employee count at NEOS Therapeutics is 150.
What does NEOS Therapeutics do?
Neos is a pharmaceutical company focused on development, manufacturing and commercialization of ADHD medications. Approved medicine includes adzenys XR-ODT (amphetamine orally disintegrating tablet) for ADHD. Product is developed for extended release using its proprietary technology platform. Another product includes generic hydrocodone polistirex and chlorpheniramine polistirex extended-release (XR) oral suspension. Pipeline includes Methylphenidate extended release orally disintegrating tablet and amphetamine oral suspension in clinical development stage.
Who are the top competitors of NEOS Therapeutics?
What products or services does NEOS Therapeutics offer?
NEOS Therapeutics offers ADHD Therapeutics, Pediatrics Products, RxCONNECT, and AR101 (enzastaurin).
Who are NEOS Therapeutics's investors?
NEOS Therapeutics has 6 investors. Key investors include Burrill and Company, Deerfield, Presidio Partners, Delaware Street Capital, and Essex Capital.